Ishares Msci Italy ETF vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Ishares Msci Italy ETF trades at $55.99 (market cap $1.17B), while Iovance Biotherapeutics Inc. Common Stock trades at $13.5 (market cap $5.85B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 5× Ishares Msci Italy ETF's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Ishares Msci Italy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 52 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| EWI | IOVA | |
|---|---|---|
Market Cap | $1.17B | $5.85B |
Volume | 862,654 | 14,517,176 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $14.82 |
52-Week Low | $50.31 | $1.81 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | — | $5.78B |
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.35, down 2.74% on the day, reflecting a bearish technical outlook with all moving averages signaling sell. The ETF provides exposure to Italian financials, utilities, and industrials, benefiting from EU recovery investments and sector consolidation. Recent news highlights ECB rate hikes and eurozone economic concerns, with energy-driven inflation posing headwinds.
The outlook remains cautious due to macroeconomic pressures from rising interest rates and inflation, though structural investments in Italian infrastructure offer long-term potential. Key risks include eurozone volatility and energy price shocks, while technical indicators suggest near-term weakness. Investors should weigh sector-specific strengths against broader market sentiment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →